Lotemox Eye Drop is a combination ophthalmic solution containing Loteprednol etabonate 0.5% w/v, a corticosteroid with potent anti-inflammatory properties, and Moxifloxacin 0.5% w/v, a broad-spectrum fluoroquinolone antibiotic. This dual-action formulation is indicated for the treatment of ocular inflammatory conditions accompanied by bacterial infections or at risk of secondary bacterial contamination. Loteprednol etabonate acts by inhibiting the release of inflammatory mediators, thereby reducing redness, swelling, and discomfort associated with ocular inflammation. Moxifloxacin exhibits bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively targeting a wide range of gram-positive and gram-negative pathogens commonly implicated in ocular infections. Lotemox Eye Drop is typically prescribed for conditions such as bacterial conjunctivitis, keratitis, and postoperative inflammation following ocular surgery. The combination therapy ensures simultaneous management of inflammation and infection, promoting faster recovery and minimizing complications. It should be used strictly under ophthalmologic supervision, with caution in patients with known hypersensitivity to corticosteroids or fluoroquinolones. Adverse effects may include transient burning or stinging upon instillation, increased intraocular pressure with prolonged use, and rare occurrences of secondary infections. Proper dosing and duration as advised by a healthcare professional are essential to optimize therapeutic outcomes and prevent resistance development.